AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology ? as well as infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
In October 2013?AstraZeneca’s global biologics research and development arm, MedImmune, acquired Spirogen, a biotech company focused on antibody-drug conjugate technology for use in oncology.
Antibody-drug conjugates are a clinically-validated cancer drug technology that offers both high potency and selective targeting of cancer cells. Spirogen?s proprietary pyrrolobenzodiazepine (PBD) technology attaches highly potent cytotoxic agents, or ?payloads? to specific cancer-targeting antibodies using biodegradable ?linkers?. This targeting optimises the delivery of the cancer drug to the tumour cells only and provides the greatest degree of tumour killing while minimising the toxicity to the patient.
2 Kingdom Street